Phase 2 N=46 Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study
Allergic Rhinitis
Primary: Total Nasal Symptom Score After Nasal Allergen Challenge (NAC) — 3.37; 4.71 score on a scale — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=102 Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen
Seasonal Allergy
Primary: Area Under the Curve [AUC](Total Score of Symptoms Taking Into Account the Total 5 Symptom Score (T5SS) and Consumption of Rescue Medications (RM) on the Y-axis, and…
Phase 3 N=445 A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis
Allergy
Primary: Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Peak Grass Pollen Season (PGPS) — 7.10; 5.22 score on a scale — p=0.0036
Phase 1 N=89 Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
Seasonal Allergic Rhinitis
Primary: Average of Rhinoconjunctivitis Total Symptom Score (ARTSS) ]0-4] Hours — 4.88; 6.84 Units on a scale (range: 0 to 18) — p=0.0003
Phase 3 N=473 Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis
Allergic Rhinitis Due to Grass Pollens
Primary: Combined Score (CS) — 0.32; 0.45 Units on a scale (range: 0 to 3) — p=0.0003
Phase 3 N=1,501 A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
Rhinitis Allergic · Conjunctivitis
Primary: Average Total Combined Rhinoconjunctivitis Daily Symptom Score (DSS) and Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire Grass Pollen Season (GPS)…
Phase 3 N=107 Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis
Seasonal Allergic Rhinitis
Primary: The Primary Efficacy Endpoint is Change From Baseline to End of Treatment of Phleum Pratense Specific Immunoglobulin G4 (IgG4) in Serum — 0.684; 0.050 mgA/L
Phase 3 N=555 Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
Seasonal Allergic Rhinitis · Rhinoconjunctivitis
Primary: Combined Symptom and Medication Score (CSMS) Averaged Over the Peak Grass Pollen Season (GPS) — 1.08; 1.34 score on a scale — p=0.00048
Phase 3 N=381 Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis
Primary Disease
Primary: Average Adjusted Symptom Score (AAdSS) — 5.58; 6.07 Units on a scale (range: 0 to 18) — p=0.2344
Phase 3 N=628 Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis
Allergy
Primary: Average Rhinoconjunctivitis Total Symptom Score — 4.72; 3.58; 3.74; 4.93 Units on a scale (range: 0 to 18) — p=0.0006
N/A N=20 Immune-modulatory Effect of Probiotic Strain on Grass Pollen Allergic Individuals
Seasonal Allergic Rhinitis
Primary: Comparison of Th2 Cytokines (IL-13) Between Placebo and Probiotic Groups at Baseline (Beginning of Product Intake), 4 Weeks (Mid Period of Product Intake) and 8 Weeks…
Phase 4 N=93 The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation
Allergic Rhinoconjunctivitis
Primary: Change in Total Nasal Symptom Score (TNSS) From Baseline to Post-treatment. — 2.3; 2.2 Scores on a scale
Phase 3 N=278 Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis
Allergy
Primary: Average Rhinoconjunctivitis Total Symptom Score (ARTSS) — 3.25; 4.51 Units on a scale (range: 0 to 18) — p=0.0010
N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Phase 2 N=126 Herbal Treatment for Perennial Allergic Rhinitis
Perennial Allergic Rhinitis
Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score
Phase 3 N=345 Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
Rhinoconjunctivitis · Rhinitis · Conjunctivitis
Primary: Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS) — 4.62; 6.25 Units on a Scale — p==0.001
Phase 2 N=103 Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy
Allergic Rhinitis
Primary: Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) (0-1 Hour (hr) Post Peak TNSS) in Response to Post Nasal Allergen Challenge (NAC)…
Phase 2 N=47 Effects of Broccoli Sprout Extract on Allergy Rhinitis
Rhinitis,Allergic
Primary: Total Nasal Symptom Score (TNSS) Change From Baseline to 3 Weeks of Randomly Assigned Treatment — -.5277; -.5484; -.8359; -.181 score on a scale
Phase 2 N=168 Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
Allergic Rhinitis · Allergic Rhinoconjunctivitis
Primary: Mean Total Symptom Score (TSS) After 10 Months of Treatment (Visit 6) Compared to Placebo — 10.01; 8.06; 8.19; 7.69 Score on a scale — p=0.057
Phase 3 N=633 Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets
Allergy
Primary: Average Adjusted Symptom Score (AAdSS) — 3.39; 3.25; 5.21 Units on a scale (range: 0 to 18) — p=< 0.0001
Phase 4 N=102 Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
Rhinitis, Allergic, Seasonal
Primary: Percentage of Participants Who Experienced at Least One Event of Local Swelling — 13.7; 21.6; 14.7 Percentage of Participants
Phase 3 N=353 Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
Allergic Rhinitis · Conjunctivitis
Primary: Combined Symptom and Medication Score (CSMS) in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo — 7.503; 8.498 Scores on a Scale — p=0.0497
Phase 2 N=199 Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
Allergic Rhinoconjunctivitis · Grass Pollen Allergy
Primary: TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) at Year 3 — 2.85; 3.61; 4.48 hr*TNSS — p=<0.001
N/A N=434 Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy
Allergic Rhinitis
Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants
Phase 3 N=1,992 The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)
Rhinitis, Allergic, Perennial
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic Rhinitis — -0.37; -0.44 Score on…
Phase 3 N=1,079 Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over First 2 Weeks of Treatment Period — -0.23; -0.33; -0.45 Scores on a scale
Phase 3 N=1,214 Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment Period — -0.38; -0.47; -0.29 Scores on a scale
Phase 3 N=1,365 Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)
Perennial Allergic Rhinitis
Primary: Mean Change From Baseline in Daytime Nasal Symptoms Score — -0.39; -0.45; -0.36 Scores on a scale
Phase 3 N=716 Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)
Allergic Rhinitis
Primary: Change From Baseline in Participant's AM/PM PRIOR Total 5 Symptom Score (T5SS) Over Days 1 to 29 of Treatment — 9.63; 9.55; -3.76; -2.87 units on a scale — p=<.001
Phase 2 N=617 Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline (Pre-Dose) Twice Daily Averaged Subject-rated Reflective Total Nasal Symptom Score (TNSS) — -1.19; -1.58; -1.68; -1.63 score on a scale